Also, conventional biomarkers used in NSCLC and other cancers such as smoking status, tumor mutation burden (TMB), and programmed cell death-ligand 1 (PD-L1) expression is not approved in SCLC clinical practice [3]. Here, CD274 is linked to neoplasm.